(3S)-3-Amino-ε-caprolactam | 948834-78-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S)-3-Amino-ε-caprolactam
• 英文别名: 3-amino-ε-caprolactam；3-(S)-amino-ε-caprolactam；(S)-3-amino-ε-caprolactam；3-Amino-Epsilon-Caprolactam；L(-)-3-amino-ε-caprolactam；'D-3-amino-epsilon-caprolactam；L(-)-3-amino-e-caprolactam；DL-3-amino-E-caprolactam；4-Aminoazepan-2-one
• CAS: 948834-78-4
• 化学式: C₆H₁₂N₂O
• 分子量: 128.174
• InChiKey: VTQGYRVGBASLDF-UHFFFAOYSA-N

物化性质

• 沸点：
  315.1±35.0 °C(Predicted)
• 密度：
  1.031±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3S)-3-Amino-ε-caprolactam 、 乙醚 在 甲酸 、 CDI 作用下， 以 二氯甲烷 为溶剂， 以48%的产率得到3-formylamino-ε-caprolactam
  参考文献：
  名称：

  Pharmaceutical compositions comprising 3-amino-.epsilon.-caprolactames

  摘要：

  揭示了用于增强学习和记忆过程的药物组合物，其活性原则为一种具有化学式（1）的3-氨基-ε-己内酰胺 ##STR1## 其中R选自氢、甲酰和乙酰的群。口服或注射途径可用的单剂量形式的药物组合物包括约100至500毫克的化合物（1）。

  公开号：

  US05166150A1

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Thiazolo (5,4-B)azepine compounds
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04956360A1

  公开（公告）日：1990-09-11

  New thiazolo[5,4-b]azepine compounds represented by ##STR1## wherein R.sup.1 is a hydrogen atom, an aliphatic group which may be substituted, a carboxylic acyl group which may be substituted or a sulfonic acyl group which may be substituted; R.sup.2 is a hydrogen atom, an aromatic group which may be substituted or an aliphatic group which may be substituted, which are capable of e.g., inhibiting lipoperoxide formation.

  新的噻唑并[5,4-b]螂环化合物由##STR1##所代表，其中R.sup.1是氢原子，可能被取代的脂肪基团，可能被取代的羧酰基团或可能被取代的磺酰基团；R.sup.2是氢原子，可能被取代的芳香基团或可能被取代的脂肪基团，这些化合物能够抑制脂过氧化物的形成。
• PEPTIDE DERIVATIVES
  申请人：——

  公开号：US20020103335A1

  公开（公告）日：2002-08-01

  The invention concerns pharmaceutically useful peptide derivatives of the formula (I), P-AA I -AA 2 -AA 3 -AA 4 -AA 5 -AA 6 -AA 7 -AA 8 -Q, in which P, AA 1, AA 2, AA 3 , AA 4, AA 5, AA 6, AA 7, AA 8, and Q have the various meanings defined herein and their pharmaceutically accentable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

  该发明涉及公式(I)的药用肽衍生物，P-AA 1 -AA 2 -AA 3 -AA 4 -AA 5 -AA 6 -AA 7 -AA 8 -Q，其中P，AA 1，AA 2，AA 3，AA 4，AA 5，AA 6，AA 7，AA 8和Q具有本文中定义的各种含义及其药用盐，以及含有它们的药物组合物。这些新型肽衍生物对于治疗MHC II类依赖性T细胞介导的自身免疫或炎症性疾病，如类风湿性关节炎，具有价值。该发明还涉及新型肽衍生物的制造过程以及化合物在医学治疗中的使用。
• Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
  申请人：——

  公开号：US20030105077A1

  公开（公告）日：2003-06-05

  The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. 1

  本发明涉及公式I的治疗活性和选择性DPP-IV酶抑制剂，包括该化合物的药物组合物以及利用这些化合物制备用于治疗受DPP-IV失活蛋白质相关的疾病的药物，如2型糖尿病和肥胖症。
• Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
  申请人：——

  公开号：US20030236272A1

  公开（公告）日：2003-12-25

  The present invention is related to a method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states comprising administering inhibitors of the enzymes NEP and DPP-IV to individuals suffering from one or more of those conditions. Inhibition of the activity of the two enzymes will potentiate the insulin releasing activity of endogenous GLP-1 and other DPP-IV substrates like GIP.

  本发明涉及一种治疗糖尿病、高血压、慢性心力衰竭和液体潴留状态的方法和组合物，包括向患有这些疾病中的一个或多个的个体中施用NEP和DPP-IV酶抑制剂。抑制这两种酶的活性将增强内源性GLP-1和其他DPP-IV底物如GIP的胰岛素释放活性。